Reducing Cardiovascular Risk in Rheumatoid Arthritis: A Randomized Controlled Clinical Trial Comparing TNF Antagonists With Triple Therapy in Methotrexate Inadequate Responders
Treatments Against RA and Effect on FDG PET-CT: The TARGET Trial
Sponsor: NIH NIAMS
Enrolling: Male and Female Patients
Study Length: 6 Months
Clinic Visits: 6
IRB Number: AAAN5158
Contact: Rachel Broderick: 212-342-2713 /
Additional Study Information: The study aims to compare the effect two different RA treatments on cardiovascular health in patients who are considering a treatment change. The study is recruiting patients who are only taking methotrexate and are switching treatment due to a lack of improvement. The trial will randomize participants to take a TNF inhibitor (Enbrel or Humira) in addition to their methotrexate or to take Triple Therapy (methotrexate + sulfasalazine + hydroxychloroquine sulfate). The study will provide you with all trial medications (excluding methotrexate) for the 6-month duration of the study. Study involvement requires two FDG-PET/CT scans and six follow-up visits over a period of six months.
This study is closed
Joan Bathon, MD
Do You Qualify?
Do you have rheumatoid arthritis? Yes No
Are you taking methotrexate for rheumatoid arthritis? Yes No
Are you interested in learning more about the impact of rheumatoid arthritis medications on cardiovascular health? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Rachel Broderick